Imagion Biosystems Ltd (ASX: IBX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imagion Biosystems Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $72.99 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.04 billion
Earnings per share -0.007
Dividend per share N/A
Year To Date Return -46.90%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

Imagion Biosystems Ltd (ASX: IBX)
Latest News

IBX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Imagion Biosystems Ltd

Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and superparamagnetic relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.

IBX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
29 Jul 2021 $0.08 $0.00 0.00% 7,922,527 $0.08 $0.08 $0.07
28 Jul 2021 $0.08 $0.00 0.00% 8,782,756 $0.08 $0.08 $0.08
27 Jul 2021 $0.08 $0.00 0.00% 3,830,791 $0.08 $0.08 $0.08
26 Jul 2021 $0.08 $0.00 0.00% 5,966,321 $0.08 $0.08 $0.08
23 Jul 2021 $0.08 $0.00 0.00% 2,455,951 $0.09 $0.09 $0.08
22 Jul 2021 $0.09 $0.00 0.00% 1,743,626 $0.09 $0.09 $0.08
21 Jul 2021 $0.09 $0.00 0.00% 4,449,007 $0.09 $0.09 $0.09
20 Jul 2021 $0.09 $0.00 0.00% 6,741,433 $0.09 $0.09 $0.08
19 Jul 2021 $0.09 $0.00 0.00% 1,519,269 $0.09 $0.09 $0.09
16 Jul 2021 $0.09 $0.00 0.00% 1,021,619 $0.09 $0.09 $0.09
15 Jul 2021 $0.09 $0.00 0.00% 3,431,734 $0.09 $0.09 $0.09
14 Jul 2021 $0.09 $0.00 0.00% 1,727,288 $0.09 $0.09 $0.09
13 Jul 2021 $0.09 $0.00 0.00% 2,711,474 $0.09 $0.09 $0.09
12 Jul 2021 $0.09 $0.00 0.00% 4,024,033 $0.09 $0.09 $0.09
09 Jul 2021 $0.09 $0.00 0.00% 6,179,690 $0.09 $0.10 $0.09
08 Jul 2021 $0.09 $0.00 0.00% 6,705,844 $0.09 $0.09 $0.09
07 Jul 2021 $0.09 $0.00 0.00% 5,522,321 $0.10 $0.10 $0.09
06 Jul 2021 $0.09 $0.00 0.00% 2,644,165 $0.10 $0.10 $0.09
05 Jul 2021 $0.10 $0.00 0.00% 2,051,068 $0.10 $0.10 $0.10
02 Jul 2021 $0.10 $0.00 0.00% 1,466,022 $0.10 $0.10 $0.10
01 Jul 2021 $0.10 $0.00 0.00% 3,941,206 $0.10 $0.11 $0.10
30 Jun 2021 $0.10 $0.00 0.00% 5,724,473 $0.10 $0.10 $0.10

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
22 Oct 2020 Robert Proulx Issued 2 $190,000
Conversion of securities.
22 Oct 2020 Robert Proulx Exercise 2 $190,000
Conversion of securities. 5,000,000 - Performance Rights
10 Sep 2020 Robert Proulx Issued 2 $230,000
Conversion of securities.
10 Sep 2020 Robert Proulx Exercise 2 $230,000
Conversion of securities. 7,500,000 - Performance Rights
06 Aug 2020 Jovanka Naumoska Issued 500 $29,000
Issue of options.
06 Aug 2020 Dianne Angus Issued 500 $29,000
Issue of options.
06 Aug 2020 Michael (Mike) Harsh Issued 500 $29,000
Issue of options.
06 Aug 2020 Mark Van Asten Issued 500 $29,000
Issue of options.
06 Aug 2020 David Ludvigson Issued 500 $29,000
Issue of options.
06 Aug 2020 Robert Proulx Issued 6 $348,000
Issue of options. As per announcement on 11/08/2020.
06 Aug 2020 Robert Proulx Sell 8 $504,600
As advised by the company. No nature of change is mentioned.
10,000,000 - Performance Rights
06 Aug 2020 Robert Proulx Issued 10 $580,000
Issue of securities. 18,700,000 - Performance Rights.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Dianne Angus Non-Executive Director May 2020
Ms Angus has worked as a senior executive within the biotechnology, agritech and healthcare sectors for over twenty years and currently serves as non-executive director with Bionic Vision Technologies Limited. She has built competitive and differentiated product portfolios, from investment in research and product development to commercialisation and market entry. She has created global industry partnerships to accelerate asset development, financing and provide reputational validation & endorsement. With eighteen years experience in listed companies, she has expertise in corporate governance, capital raising and stakeholder engagement within the listed capital market sector. She is a member of the Disclosure Committee.
Mr Michael (Mike) John Harsh Non-Executive Director Feb 2017
Mr Harsh has over 36 years service to GE, mostly with GE Healthcare on his resume, he is in the processes of transforming platform technologies into medical diagnostic products. He is currently director of Endra Life Sciences (Since 2016), EmOpti, Inc. (Since 2015) and Compute Health Acquisition Corp (Since 2021) and is a former director of FloDesign (2015-2019) and NociMed (2019-2020). He is a co-founder and Chief Product Officer of Terapede Systems. He is a Member of the Risk Committee.
Mr Mark Gerald Van Asten Non-Executive Director Dec 2016
Mr Asten has over 30 years of experience in the medical diagnostics and life sciences industry. His time has been in international business development, strategic planning and introduction of new technology. Through Diagnostic Technology, a company he founded, he has been in charge for the development and introduction of a number of technology platforms and technologies into mainstream healthcare use, including HPV DNA testing for cervical cancer screening and the molecular monitoring for both viral infections and cancer treatments. He holds an Adjunct Senior Lectures position at the School of Biotechnology and Biomolecular Science, University of NSW where he has collaborated on a number of research projects related to biosynthetic pathways in bacteria. He is a former director of Cimtech Limited. He is a Member of the Risk Committee.
Mr David Gerald Ludvigson Non-Executive Director Mar 2017
Mr Ludvigson is currently President & CEO at Nanomix. He is a financial and operating executive with over 35 years of international experience in life sciences and technology companies including Biogen (formerly IDEC Pharmaceuticals), Matrix Pharmaceutical, Nanogen, and MIPS Computer Systems. His experience over 15 years in the diagnostics arena has led range of product efforts from concept to market launch. He has conducted transactions including range of acquisitions, corporate partnerships, technology and intellectual property licensing agreements, and OEM relationships and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources. He is also a director of China Stem Cells Ltd (Since 2010). He is a Member of the Risk and Disclosure Committee.
Mr Robert Romeo Proulx Executive ChairmanExecutive Director Dec 2016
Mr Proulx has over 25 years experience in life science and medical device products through development and commercialisation and served the predecessor company, Senior Scientific as President and Chief Operating Officer. His previous employment experience includes President / General Manager for Silicon Biosystems and a career in marketing and sales management. Some of his other experience include: Vice President Marketing and Sales for Nanogen Inc.; Senior Vice President of Marketing and Business Development at Gene Logic; and General Manager, Life Sciences at IGEN International Inc.
Ms Jovanka Naumoska Non-Executive Director Dec 2016
Ms Naumoska has experience in legal and regulatory issues pertaining to medical imaging technology. Jovanka serves Australian scientific development organisations in an expert capacity on matters relating to corporate law, business operations, intellectual property development and regulatory compliance. She formerly held the role of Company Secretary role for Imagion Biosystems up until 8 December 2020. She is director of Security Matters Limited and National Accreditation Authority for Translators and Interpreters Limited. She is a member of the Disclosure Committee.
Mr Geoff Hollis Chief Financial OfficerCompany Secretary Dec 2020
-
Geoff Hollis Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 56,856,953 5.53%
HSBC Custody Nominees (Australia) Limited i 35,978,808 3.50%
Citicorp Nominees Pty Limited 22,674,960 2.21%
The Board Of Regents Of The University Of Texas System 10,529,053 1.02%
Mr Anthony Faillace 10,361,838 1.01%
Mr Haojie Li 9,850,000 0.96%
G & D Finn Pty Ltd 8,000,000 0.78%
J P Morgan Nominees Australia Pty Limited 7,596,510 0.74%
Mr Anestis Lazaridis 7,583,365 0.74%
Mr Yusuf Kucukbas <Yasep A/C> 7,400,000 0.72%
Mr Gregory John Howlett & Mrs Margaret Wilhelmina How 6,740,000 0.66%
Mr Robert Reveley 6,100,000 0.59%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 5,294,200 0.52%
Bairdos Pty Ltd 5,000,000 0.49%
Rookharp Capital Pty Limited 5,000,000 0.49%
E & W Nominee Pty Ltd <Liang Family Super Fund A/C> 4,750,000 0.46%
Mr Feeras Najjar <Najjar Family A/C> 4,500,000 0.44%
Hawgood Pty Ltd 4,435,294 0.43%
Mr Yoanto Wakimin 4,307,260 0.42%
Dr Russell Kay Hancock 4,000,000 0.39%

Profile

since

Note